NeoImmuneTech KRX:950220KOSDAQ
네오이뮨텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days6
DART filings, 7 days0
Articles tracked11since Sep 11
In Q2 2026, NeoImmuneTech reported revenue of ₩1m, up 4383.8% year on year, and an operating loss of ₩3m. NeoImmuneTech (네오이뮨텍) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 21 with 5 articles. The most common catalyst was contracts & orders (1). It was most often mentioned alongside IL.
Filing signals 4 quarters of losses Screener
NeoImmuneTech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1m | +4383.8% | −₩3m | −₩0m |
| Q1 2026 | ₩0m | +3847.7% | −₩4m | −₩5m |
| Q4 2025 derived | ₩0m | – | −₩4m | −₩7m |
| Q3 2025 | ₩0m | -98.4% | −₩3m | −₩4m |
| Q2 2025 | ₩0m | – | −₩5m | −₩5m |
| Q1 2025 | ₩0m | – | −₩6m | −₩6m |
| Q4 2024 derived check units | −₩1m | – | −₩6m | −₩6m |
| Q3 2024 | ₩1m | – | −₩8m | −₩8m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
NeoImmuneTech top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest NeoImmuneTech news Korean headlines
-
Major네오이뮨텍 'NT-I7' 기술이전 파트너, 日 타나베파마 항체 도입
2 more on this story · 2 outlets
- 네오이뮨텍 'NT-I7' 개발 파트너사, 日 타나베파마 항체 도입핀포인트뉴스 · Sep 30 16:57
- 네오이뮨텍 파트너 톨러런스 바이오, 타나베파마 항체 도입메디포뉴스 · Sep 30 18:49
-
네오이뮨텍, CAR-T 병용 ‘NT-I7’ 임상 2차 용량군 진입
1 more on this story · 1 outlets
- 네오이뮨텍, NT-I7·CAR-T 병용 1상서 첫 용량군 안전성 확인한국경제 · Sep 21 08:39